1. Endocan as a marker of endotheliitis in COVID-19 patients: modulation by veno-venous extracorporeal membrane oxygenation, arterial hypertension and previous treatment with renin-angiotensin-aldosterone system inhibitors.
- Author
-
Reina-Couto M, Alves D, Silva-Pereira C, Pereira-Terra P, Martins S, Bessa J, Teixeira-Santos L, Pinho D, Morato M, Dias CC, Sarmento A, Tavares M, Guimarães JT, Roncon-Albuquerque R, Paiva JA, Albino-Teixeira A, and Sousa T
- Subjects
- Humans, Male, Middle Aged, Female, Aged, Adult, Angiotensin-Converting Enzyme Inhibitors therapeutic use, COVID-19 blood, COVID-19 therapy, COVID-19 complications, Hypertension blood, Hypertension drug therapy, Extracorporeal Membrane Oxygenation, Proteoglycans blood, Biomarkers blood, Renin-Angiotensin System drug effects, E-Selectin blood, Neoplasm Proteins blood, Intercellular Adhesion Molecule-1 blood, Vascular Cell Adhesion Molecule-1 blood
- Abstract
Background and Aims: Endocan has been scarcely explored in COVID-19, especially regarding its modulation by veno-venous extracorporeal membrane oxygenation (VV-ECMO), hypertension or previous renin-angiotensin-aldosterone system (RAAS) inhibitors treatment. We compared endocan and other endotheliitis markers in hospitalized COVID-19 patients and assessed their modulation by VV-ECMO, hypertension and previous RAAS inhibitors treatment., Material and Methods: Serum endocan, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin were measured in "severe" (n = 27), "critically ill" (n = 17) and "critically ill on VV-ECMO" (n = 17) COVID-19 patients at admission, days 3-4, 5-8 and weekly thereafter, and in controls (n = 23) at a single time point., Results: Admission endocan and VCAM-1 were increased in all patients, but "critically ill on VV-ECMO" patients had higher endocan and E-Selectin. Endocan remained elevated throughout hospitalization in all groups. "Severe" and "critically ill" hypertensive patients or previously treated with RAAS inhibitors had higher endocan and/or VCAM-1, but in VV-ECMO patients the raised endocan values seemed unrelated with these factors. Among all COVID-19 hypertensive patients, those with previous RAAS inhibitors treatment had higher endocan., Conclusions: In our study, endocan stands out as the best marker of endotheliitis in hospitalized COVID-19 patients, being upregulated by VV-ECMO support, hypertension and previous RAAS inhibitor treatment., Competing Interests: Declarations. Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: The CHUSJ Health Ethics Committee approved this study [CES 75-16], with project amended specifically for inclusion of subjects with COVID-19, within the scope of a RESEARCH 4 COVID-19 grant from FCT (special support for rapid implementation projects for innovative response solutions to COVID-19 pandemic)]. All eligible patients provided written informed consent to participate in the study. For ICU patients unable to give consent, this was solicited to their next of kin. These patients provided informed consent retrospectively, where possible. Blood donor volunteers provided oral informed consent. Consent for publication: All authors agree to publish this article., (© 2025. The Author(s).)
- Published
- 2025
- Full Text
- View/download PDF